Ascorbic acid treatment for Charcot-Marie-Tooth disease type 1A

Ascorbic acid treatment for Charcot-Marie-Tooth disease type 1A - Ascorbic acid treatment for CMT1A

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000036332

Enrollment

Registered

2019-03-28

Start date

2019-06-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Charcot-Marie-Tooth diease type 1A

Interventions

Ascorbic acid treatment: 20mg/kg/day, dayly

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Genetically Confirmed PMP duplication 2. Normal blood examination 3. Normal urinary analysis 4. Informed consent obtained

Exclusion criteria

Exclusion criteria: 1. Unsuitable patient judged by the medical doctor

Design outcomes

Primary

Measure	Time frame
Charcot-Marie-Tooth disease neurological score will be used for primary outcome every 24 weeks after ascorbic acid treatment	—

Secondary

Measure	Time frame
Electrophysiological examination including latency, conduction velocity, temporal dispersion and compund muscle action potential.	—

Countries

Japan

Contacts

Public ContactReiko Aoyagi

Chiba University Hospital Department of Clinical Investigation

prc-jim@chiba-u.jp043-222-7171

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026